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ABSTRACT
Apicoplast, an essential organelle of human malaria
parasite Plasmodium falciparum contains a  35kb
circular genome and is a possible target for therapy.
Proteins required for the replication and mainten-
ance of the apicoplast DNA are not clearly known.
Here we report the presence of single–stranded
DNA binding protein (SSB) in P falciparum. PfSSB
is targeted to the apicoplast and it binds to
apicoplast DNA. A strong ssDNA binding activity
specific to SSB was also detected in P. falciparum
lysate. Both the recombinant and endogenous
proteins form tetramers and the homology
modelling shows the presence of an oligosacchar-
ide/oligonucleotide-binding fold responsible for
ssDNA binding. Additionally, we used SSB as a
tool to track the mechanism of delayed death phe-
nomena shown by apicoplast targeted drugs
ciprofloxacin and tetracycline. We find that the
transport of PfSSB is severely affected during the
second life cycle following drug treatment.
Moreover, the translation of PfSSB protein and not
the transcription of PfSSB seem to be down-
regulated specifically during second life cycle
although there is no considerable change in
protein expression profile between drug-treated
and untreated parasites. These results suggest
dual control of translocation and translation of
apicoplast targeted proteins behind the delayed
death phenomena.
INTRODUCTION
Plasmodium falciparum, the causative agent of most severe
form of human malaria belongs to the phylum
apicomplexa (1). The apicomplexan parasites possess a
non-photosynthetic plastid like organelle called
apicoplast. The apicoplast is the site for several biosyn-
thetic pathways (fatty acid, isoprenoid, heme biosynthesis)
that are central to the core cellular functioning of the
parasite (2). The biosynthetic pathways located within
the apicoplast provide novel sites of drug intervention
against the malaria disease (3). Moreover, the house
keeping metabolic processes like DNA replication, tran-
scription and translation operative within the apicoplast
are prokaryotic in nature and therefore they are good
targets of existing antibacterials or novel drugs (4).
The  35kb, extremely A+T rich ( 86%) apicoplast
DNA is circular and replicates via a D-loop/bi-directional
theta mode in late trophozoite/early schizont stages of
intraerythrocytic life cycle (5). The origins of apicoplast
DNA replication have been mapped in the inverted repeat
(IR) regions (6). The apicoplast genome houses only 68
open reading frames (ORFs) for rRNAs, tRNAs, ribo-
somes, RNA polymerase, translational elongation factor
(EF-Tu), ClpC chaperone and Fe–S cluster protein (SufB)
(1,7). None of the ORFs on the apicoplast DNA codes for
replication protein. Most of the proteins involved in the
apicoplast metabolic pathways are encoded in the nucleus,
synthesized in the cytoplasm and subsequently imported
into the apicoplast (2). The nuclear encoded proteins are
targeted to apicoplast by the apicoplast localization signal
that is cleaved off from the protein once inside the
apicoplast (8). Recently, a  220kDa nuclear encoded
multifunctional enzyme PfPRex (P. falciparum plastidic
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to localize in the apicoplast. This enzyme has three im-
portant activities (helicase, primase and polymerase)
associated with DNA replication (9). A histone like
protein (HU) exhibiting the DNA condensation property
is imported into apicoplast suggesting its role in organiza-
tion of apicoplast genome (10). We and others have shown
that the gyrase subunits present in the parasite are
targeted to apicoplast where they might be involved in
negative supercoiling of the DNA circle, an essential
step for the replication process (11,12). Consistent with
the above ﬁndings, quinolone (ciproﬂoxacin) or
coumarin (coumermycin, novobiocin) antibiotics target
the parasitic gyrase and inhibit the apicoplast DNA rep-
lication leading to the parasite death (12,13).
Since apicoplast is of prokaryotic origin, several anti-
biotics against bacterial replication, transcription and
translation processes have been used successfully to
block parasitic growth. However, majority of these anti-
biotics show typical delayed growth phenotype,
characterized by defect in parasite growth and decrease
in parasitemia only during second life cycle following the
addition of these drugs (4). It has been suggested that
these drugs affect apicoplast morphology, segregation
and most importantly the transport of essential proteins
in the apicoplast. Using fusion protein containing
apicoplast signal sequence of acyl carrier protein (ACP)
and GFP, the effect of these drugs on protein transloca-
tion have been studied (14,15). However, no endogenous
apicoplast targeted protein involved in house keeping
function has been followed after drug treatment in the
above studies. Neither the transcription and translation
status of apicoplast targeted proteins was investigated
simultaneously in the presence of these drugs.
To gain further insight into the enzymology of
P. falciparum apicoplast DNA replication, we wanted to
study another essential key protein, the homologue of bac-
terial single-stranded DNA binding protein (SSB) (16).
The prokaryotic type circular P. falciparum apicoplast
DNA suggests a possible requirement of bacterial type
SSB for various DNA metabolic processes in that organ-
elle. The analysis of the parasite genome indeed reveals the
presence of a bacterial type ssb on the chromosome V of
the nuclear DNA (PFE0435c). The N-terminal extension
in the primary sequence of the protein is predicted to be a
potential apicoplast targeting sequence.
SSBs are known to play essential roles in many aspects
of nucleic acid metabolism including DNA replication,
recombination and repair. SSBs protect and stabilize the
single-stranded DNA (ssDNA) intermediates as well as
remove secondary structures in the DNA. Any misstep
in DNA replication or a failure to properly recombine
or repair DNA can lead to gross aberrations in the
genome, signifying the role of SSBs in these processes (17).
In eukaryotes, a heterotrimeric complex called replica-
tion protein A (RPA) (18) carries out the ssDNA binding
activity in the nucleus. Mitochondrial DNA replication
involves the ssDNA binding protein (mtSSB) that is
quite distinct from nuclear RPA. mtSSB shows a great
degree of sequence homology with bacterial SSB (19). In
P. falciparum, however, ssDNA binding activity in the
nucleus has been reported earlier corresponding to the
large subunit ( 55kDa) of RPA (20).
SSB proteins from different organisms share sequence
homology as well as distinct biochemical and structural
characteristics. The SSBs have a common oligosacchar-
ide/oligonucleotide-binding fold (OB fold) which binds
to ssDNA. The SSBs from all prokaryotic organisms
have an acidic C-terminal tail that is essential for DNA
replication by mediating protein–protein interactions at
the replication fork (17). In solution, SSBs are found in
different oligomeric states. They are found as homodimers
(Bacteriophages, Thermus thermophilus, T. aquatics and
Deinococcus radiodurans), heterotrimer (eukaryotic
RPAs) and homotetramers (mitochondrial and most pro-
karyotic SSBs) (21).
We report here the presence of a prokaryotic SSB
homologue in the protozoan parasite P falciparum
(PfSSB) that is encoded in the nucleus and targeted to
the apicoplast. PfSSB is expressed in all the three stages
of intraerythrocytic life cycle of parasite and binds specif-
ically to apicoplast DNA. Both recombinant as well as
endogenous PfSSB proteins form tetramers in solution
like Escherichia coli SSB protein although it fails to com-
plement E. coli ssb mutant cells suggesting subtle differ-
ences between these proteins possibly due to the
differences in the C-terminal region. Consistent with the
expression of PfSSB in the parasites, a strong ssDNA
binding activity speciﬁc to PfSSB was found in the
parasite lysate. Further, we show that inhibitors against
apicoplast replication and translation machinery
modulate PfSSB expression and function signiﬁcantly,
possibly by affecting the translocation of the protein to
the apicoplast as well as intervening with the translation of
the protein during the second life cycle following drug
treatment. These results suggest a mechanism for
delayed death phenomena shown by parasites treated
with drugs that affect apicoplast house keeping functions.
MATERIALS AND METHODS
Construction of recombinant expression vector
The expression vector pET28a (Novagen) with N-terminal
His6-tag was used to clone ssb. Pfssb was ampliﬁed
(omitting apicoplast targeting signal) from the genomic
DNA by means of polymerase chain reaction using
triple master mix PCR enzyme (Eppendorf) and speciﬁc
primers (P1–P2). Please see Table 1 for all primer se-
quences. The ampliﬁed DNA product was double
digested with BamHI and XhoI restriction enzymes (New
England Biolabs), ligated into pET28a expression vector
and used to transform DH10b bacterial cells. The recom-
binant clone was subsequently sequenced and the
sequence perfectly matched with the sequence reported
in PLASMODB.ORG (PFE0435c).
Protein puriﬁcation
His6-PfSSB was puriﬁed using Ni–NTA resin (QIAGEN)
as per the protocol suggested by the vendor. The details of
the protocol are described in the supplementary section
(‘Materials and Methods’ section). GST-PfSSB and GST
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4B beads as described in the Supplementary Data
(‘Materials and Methods’ section).
Immunodepletion assay
GST-PfSSB (50–60mg) or GST bound glutathione
sepharose 4B beads were incubated overnight with 30ml
crude anti-SSB sera at 4 C. These beads were separated by
low-speed centrifugation (3000r.p.m.) from immuno-
depleted sera. Each immunodepleted sera (3ml) were
taken out and the rest were further incubated with respect-
ive fresh protein bound beads for another 8h at 4 C. After
the second round of immunodepletion process, the sera
were separated from the beads as described earlier.
Western blot experiments were performed using four
(1–4) different PVDF strips having equal amount of
parasite lysate. The ﬁrst strip was treated with untreated
anti-SSB sera (1:5000 dilution) as control, second strip
was treated with second round GST-depleted anti-sera
whereas third and fourth strips were treated with ﬁrst
and second round GST-PfSSB depleted anti-sera with
same dilution as control. All the blots were retreated
with anti-Pf Actin sera to conﬁrm equal loading.
Electrophoretic mobility shift assay
To investigate the ssDNA binding activity of PfSSB,
EMSA was performed either using a mixture of
M13mp18 circular ssDNA and pUC18 circular dsDNA
or radiolabelled 70 base synthetic oligonucleotide as
described elsewhere (22,26). The details of the EMSA
protocol are described in the Supplementary Data
(‘Materials and Methods’ section).
Generation of antibodies
Polyclonal antibodies against puriﬁed His6-PfSSB were
raised in mice using essentially the protocol described pre-
viously by Harlow and Lane (23).
Western blotting and immunoprecipitation
Either mixed stage or synchronized parasites were released
from the host RBCs by saponin lysis and the parasites
were resuspended in 50mM Tris–Cl (pH 7.5) containing
protease inhibitor cocktail (Sigma) followed by addition
of SDS–PAGE loading buffer and boiling for 5min at
95 C. The cell lysates were resolved in 12% SDS–PAGE
and subsequently used for western blot analysis. The
immunoprecipitation was carried out using the protocol
described elsewhere (10).
Parasite culture and drug treatment
Plasmodium falciparum (3D7) strain was cultured as
described earlier (11). Synchronization of parasite
culture was obtained by treating the RBC-infected para-
sites in 5% Sorbitol (W/V) solution in every 48h at ring
stage. Study of effect of different drugs on parasites and
the modulation of PfSSB and other proteins was con-
ducted by treatment with ciproﬂoxacin (5, 10 and
15mM) or tetracyclin (10mM) or artemisinin (10, 20 and
30nM) in parasite culture containing 0.5% parasitemia in
6-well culture plate. Fresh medium with different drugs
were replaced in every 24h. Finally, parasites were har-
vested in different stages (ﬁrst or second life cycle).
MG132 (100nM) was added in the ciproﬂoxacin treated
culture during the second life cycle.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was per-
formed essentially following the protocol described by
Ram et al. (10) with appropriate modiﬁcations. Please
see the Supplementary Data (‘Materials and Methods’
section) for details.
RT-PCR analysis
Total RNA from the parasite was isolated by Trizol
method (11) RNA was treated with DNase I
(Fermentas) to avoid DNA contamination. Synthesis of
cDNA was performed by using Superscript II invitrogen
Table 1. List of primers
Primer number Name of the primer Primer sequence from 50 to 30
P1 Pf SSB fw BamH1 CGGGATCCATGAATGAGAAATCATTAAAT
P2 Pf SSB rv Xho1 CC GCTCGAGTCATTCAAATTCTTGG
P3 Pf SSB28 rvXho1 CCGCTCGAGTTCATTATTAYCATCTAACCTAT
P4 Pf SSB fw RT CAGTCAACCGAAACAAATAAC
P5 Pf SSB rv RT CATTATTATCATCTAACCTAC
P6 Pf GAPDH fw RT ATGCCAAGTAGATGTTGTATGTGAA
P7 Pf GAPDH rv RT TCGTACCATGAAACTAATTTGAAGA
P8 IRA Fw CAATATTTTAATACTGTC
P9 IRA Rv TAGCTCAGAATTAACGCTA
P10 TufA Fw GCAACACCTAATAAATTAAAG
P11 TufA Rv TAATTTTTTATTTCTGTTATAATAC
P12 Ori Fw CTTAATGATCCGATAATTATTTAG
P13 Ori Rv TTATACTTAACTACTCAACTTTAC
P14 Sir2 Fw CGTCTACTGTATCAACAGCT
P15 Sir2 Rv CACTTGACCCTTTTAATATATTT
P16 Orc5 Fw AGTTTAATATGTCAACAAATTAATAC
P17 Orc5 Rv TTATATTATCAACTCATCTAGAGG
Nucleic Acids Research, 2010,Vol.38, No. 20 7039Kit as per the manufacture’s instruction. RNA without
reverse transcriptase was considered as negative control
during cDNA synthesis. PCR was carried out with 4ml
cDNA sample or negative control by using primers for
PfGAPDH (P6–P7) or PfSSB (P4–P5). PCR products
were further analysed by agarose gel elctrophoresis.
Sucrose gradient ultracentrifugation
Sucrose gradient ultracentrifugation assay was done fol-
lowing the protocol described by Choudhury et al. (24)
Recombinant PfSSB (150mg) or 150ml P. falciparum
whole cell extract (in lysis buffer) obtained from 50ml
mixed stage parasite pellet or different marker proteins
( 200mg) were layered on top of 4.9ml 10–40% (w/v)
sucrose step gradient in a buffer containing 25mM Tris–
HCl (pH 7.5), 250mM NaCl, 2mM sodium bisulphate
and 0.05% Triton X-100. Samples were centrifuged in a
Beckman MLS-50 rotor at 35000r.p.m. for 18h at 4 C.
Several fractions ( 170ml) were collected for each protein.
Fractions of recombinant protein and marker proteins
were subjected to 10% SDS–PAGE analysis where as frac-
tions of parasite extract were TCA precipitated and sub-
jected to western blot analysis by anti-PfSSB antibodies.
Standard curve was generated using Microsoft excel ap-
plication program by plotting molecular mass as the
function of sedimentation distance for various marker
proteins, e.g. ovalbumin (43kDa), aldolase (158kDa),
catalase (232kDa), ferritin (440kDa) and thyroglobulin
(669kDa) (Amarsham Biosciences, USA). Regression
analysis using the Microsoft excel application programme
yielded the equation y=2.0155x+0.108. ‘y’ represents
the log of the molecular mass in kDa and ‘x’ represents
log of fraction number. The peak fraction numbers of re-
combinant PfSSB (fraction no. 9) and endogenous PfSSB
(fraction no. 8) were ﬁtted to the standard curve and
relative molecular masses were estimated.
Dynamic light-scattering study of Pf SSB
The particle size measurement was performed by a
dynamic light scattering (DLS) technique (mostly at scat-
tering angel=90  and laser wave length=660.00nm) on
a digital correlator (Photocor instrument, USA). Scattered
light obtained from the sample kept in a quartz cuvette
was detected by a photo multiplier tube (Hamamatsu).
The signal was converted to an intensity autocorrelation
function by a digital correlator. The data analysis was
done using CONTIN software provided by Brookhaven
instrument. Further details about DLS and data analysis
can be found elsewhere (25).
Fluorescence and confocal microscopy
Smears of parasitized RBC of different developmental
stages were made and ﬁxed in chilled methanol.
Blocking was done by incubating the slide with a
solution containing 3% BSA and 0.05% saponin in a
humidiﬁed chamber for 2h at 37 C. The slides were
washed with 1 PBS and incubated with anti-PfSSB/
anti-PfACP antibodies at 1:2000 dilutions for overnight
at 4 C. After washing the slides thoroughly with 1 PBS,
they were again incubated with 1 PBS containing
anti-mouse/anti rabbit secondary antibodies and DAPI
(Molecular probe, Invitrogen) for 1h at room tempera-
ture. Finally, the slides were washed and mounted with
anti-fed reagent and viewed under 100 oil immersion
objective. Confocal images were collected using Laser
scanning Olympus microscope or Carl Ziess Apotome
ﬂuorescence microscope and the ﬁgures were prepared
using Adobe photoshop.
Complementation assay—plasmid bumping assay
For complementation assay, E. coli RDP317 strain (a kind
gift from Dr Umesh Varshney, Indian Institute of Science,
Bangalore, India) was used. In this strain, the chromo-
somal ssb gene is replaced by a kanamycin resistance
(ssb::Kan) marker and it harbours a support plasmid
pRPZ150 (ColEl ori, TcR) coding wild-type SSB
protein. The complementation assay was performed essen-
tially following the protocol described elsewhere (26) with
some modiﬁcations as described in the Supplementary
Data (‘Materials and Methods’ section).
Metabolic labelling of parasite proteins
Synchronized parasites ( 12–14h post-invasion) were
treated with ciproﬂoxacin (10mM). Untreated and
ciproﬂoxacin treated trophozoite stage parasites during
second life cycle ( 68h post drug treatment) were
incubated with
35S-methionine (speciﬁc activity=
15mCi/ml, added to a ﬁnal concentration of 150mCi/ml)
for 3h. The parasites were then released by saponin lysis,
washed with 1 PBS and subsequently lysed in lysis
buffer (30mM Tris–HCl, pH 8.0, 300mM NaCl, 1mM
EDTA, 0.7% Triton X, Protease inhibitor cocktail). The
lysate was used for immunoprecipitation assay with
anti-PfSSB and anti-PfActin antibodies or respect-
ive pre-immune sera as described earlier (10).
Immunoprecipitated samples were further subjected to
analysis by SDS–PAGE and autoradiography.
RESULTS
PfSSB is constitutively expressed in intra-erythrocytic life
cycle of P. falciparum and it is targeted to the apicoplast
PLASMODB contains an ORF (PFE0435c) that shows
39% identity and 66% homology with E. coli SSB
(Figure 1A). It has a long stretch of 76 amino acid
residues at the N-terminus that shows putative apicoplast
targeting sequence. PfSSB also contains an extension of
28 amino acid residues at the C-terminus that does not
show homology with EcSSB. Overall, the N-terminal
ssDNA binding region (excluding the apicoplast targeting
sequence) shows more homology than the C-terminal
protein–protein interacting domain (excluding the
extreme C-terminal 28 residues) that is rich in asparagine
residues in contrast to the similar domain of EcSSB
that is rich in glycine residues (Figure 1A). Analysis of
primary amino acid sequence of PfSSB reveals evolution-
ary conserved oligosaccharide/oligonucleotide binding
domain (from amino acid 80–184) (OBD) implicated
in ssDNA binding. The three tryptophan residues
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Figure 1. Amino acid sequence alignment, protein expression proﬁle and immunolocalization of PfSSB. (A) Clustal W amino acid sequence
alignment of PfSSB with E. coli SSB (EcSSB). Identical residues are marked with ‘asterisk’ whereas ‘colon’ and ‘end note’ signs are used to
indicate strongly and weekly similar residues, respectively. (B) Coomassie-stained gel picture of induction and puriﬁcation of His6-tagged Pf SSB.
Protein markers (M) are indicated on the right. (C) The right panel shows the western blot analysis using pre-immune (PI) or immune (I) sera against
PfSSB (lanes 1 and 2) against 3D7 parasite lysate. The left panel shows the coomassie stained gel following transfer of the proteins on the membrane
(loading control) (D) Expression proﬁle of PfSSB at the different erythrocytic stages as indicated on top is shown by western blot analysis using
polyclonal antibodies against PfSSB. The same blot was reprobed with antibodies against PfActin (middle panel). The bottom panel shows the
coomassie stained gel following transfer. (E) Immunoprecipitation of PfSSB protein from parasite lysate using immune (I) or pre-immune sera (PI)
followed by western blot analysis using polyclonal antibodies against SSB. Arrowhead indicates the position of PfSSB protein. (F) Localization of
PfSSB by immunoﬂuorosecnce analysis using glass slide containing ﬁxed parasites obtained from trophozoite and schizont stages in the presence of
anti-PfSSB antibodies. DAPI indicates nuclei whereas merged panel shows the presence of PfSSB with respect to the nuclei. The last panel shows the
phase picture of parasite infected RBC. (G) Immuno-colocalization of PfSSB and apicoplast marker acyl carrier protein (ACP). Merged panel shows
the co-localization of both the proteins.
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binding in EcSSB (27) are conserved in OBD of PfSSB
(Trp-117, Trp-131, Trp-167) suggesting their possible in-
volvement in ssDNA binding. Likewise, His-132, an
amino acid residue involved in oligomerization (28) is
conserved in both the species. The crucial extreme
C-terminal conserved hydrophobic residues proline and
isoleucine found in EcSSB (involved in protein–protein
interaction) (17) are replaced by glutamic acid residues
in PfSSB suggesting difference in interacting partners
between these two proteins.
The ssb ORF excluding the signal peptide was ampliﬁed
by using speciﬁc primers (as shown in Table 1) and
genomic DNA from 3D7 strain of P. falciparum. The
ampliﬁed PCR product was subsequently cloned in the
expression vector pET28a and the recombinant construct
was further sequenced completely. The sequence of the
cloned ssb fragment was found to be identical with the
sequence reported in PLASMODB.ORG. BL21 codon
plus cells were transformed with the recombinant clone
and His6-PfSSB protein was puriﬁed using Ni–NTA
afﬁnity puriﬁcation as described in the ‘Materials and
Methods’ section (Figure 1B). Polyclonal antibodies
were generated in mice using the puriﬁed protein as
antigen.
In order to investigate whether PfSSB is expressed in the
parasites, western blot analysis was performed using
parasite lysate obtained from mixed stage parasites in
the presence of pre-immune and immune sera against
PfSSB. A speciﬁc band ( 30kDa) was obtained only in
the immune sera treated lane and not in the pre-immune
sera treated lane (right panel, Figure 1C). The left panel
shows commassie stained gel following transfer of the
proteins onto the membrane as loading control. To
crosscheck the speciﬁcity of the anti-PfSSB serum,
immunodepletion assay was performed. For this
purpose, anti-PfSSB sera were incubated overnight with
glutathione sepharose 4B beads containing GST proteins
or GST-PfSSB proteins. GST or GST-PfSSB treated sera
were further immunodepleted using fresh GST or
GST-PfSSB proteins containing beads for another 8h.
These different immunodepleted sera and untreated sera
were used for western blot analysis against parasite lysate
obtained from mixed stage parasites. We ﬁnd that both
untreated and GST protein depleted sera show a strong
band corresponding to PfSSB. However, the intensity of
the PfSSB band was reduced drastically when GST-PfSSB
imuunodepleted sera were used for western blot analysis
(Supplementary Figure S1A). The same membranes were
treated with anti-PfActin sera resulting in a strong band
corresponding to PfActin in all the lanes conﬁrming the
loading of equivalent amount of proteins in all the lanes
(Supplementary Figure S1A). The immunodepletion
results clearly indicate the speciﬁcity of the anti-PfSSB
sera. Further, the expression pattern of the endogenous
protein at the different developmental stages were
investigated by western blot analysis using anti-PfSSB
antibodies against parasite lysate obtained from
synchronized ring, trophozoite and schizont stage para-
sites. A speciﬁc band ( 30kDa) was obtained in all the
stages suggesting that PfSSB is expressed during all the
stages of the asexual developmental cycle (Figure 1D).
The deduced molecular mass of PfSSB is  24.6kDa. We
ﬁnd that PfSSB runs anomalously in SDS–PAGE consist-
ent with many other Plasmodium proteins (10). As a
loading control, the same blot was used to track the ex-
pression of PfActin at different stages (Figure 1D). To
further investigate the authenticity of the band obtained
in western blot analysis, immunoprecipitation experiment
was performed using parasite lysate and pre-immune and
immune sera against PfSSB. Western blot analysis follow-
ing immunoprecipitation indicates the presence of a
speciﬁc band in the immune sera precipitated lysate but
not in pre-immune sera treated samples (Figure 1E). These
results truly reﬂect the endogenous expression of PfSSB
and the speciﬁcity of the antibodies.
We further investigated the subcellular localization of
PfSSB during asexual developmental cycle by immuno-
ﬂuroscence assay using antibodies against PfSSB.
Distinct subnuclear spot corresponding to apicoplast
was observed in late ring/trophozoite stage parasites
with undivided nucleus (Figure 1F, ﬁrst row, top panel,)
whereas multiple subnuclear spots were observed in
multinucleated schizont stage parasites (Figure 1F,
bottom two rows, top panel). These results are consistent
with the multiplication of apicoplast organelle with
parasite growth. To further conﬁrm whether PfSSB is
located in the apicoplast organelle of the parasite,
immuno-colocalization experiment was performed using
antibodies against P. falciparum ACP (a marker for
apicoplast) and PfSSB (11). We ﬁnd that PfACP is
localized in the sub-nuclear apicoplast compartment.
Interestingly, PfSSB signal was completely merged with
the PfACP signal suggesting that PfSSB is truly localized
in the apicoplast (Figure 1F, the bottom panel).
Oligomeric status PfSSB in vitro and in vivo and
homology modelling
EcSSB forms homo-tetramer in solution (28). It will be
interesting to see the oligomeric status of recombinant
PfSSB and endogenous PfSSB from parasite lysate in
solution. For this purpose, both recombinant PfSSB and
Plasmodium lysate from mixed stage parasites were sub-
jected to sucrose density gradient centrifugation as
described in the ‘Materials and Methods’ section.
Different molecular mass markers were also used for cen-
trifugation under the same experimental conditions.
Several fractions were collected for each molecular mass
marker and peak fraction was identiﬁed (shown with
arrow heads on top, Figure 2A). Subsequently, the peak
fraction of recombinant PfSSB was identiﬁed by SDS–
PAGE and coomassie staining of the gel containing dif-
ferent fractions following centrifugation (Figure 2A, top
panel). The peak fraction of endogenous PfSSB was
identiﬁed by western blot analysis of each fraction using
anti-PfSSB antibodies (Figure 2A, bottom panel). A
standard curve was plotted using the log fraction
number (peak fraction) against molecular mass of the
standard proteins (Figure 2B). This helped us to
estimate the molecular mass of recombinant PfSSB
( 104kDa) and native PfSSB ( 92kDa). The apparent
7042 Nucleic Acids Research, 2010,Vol.38, No. 20difference in the calculated molecular masses between the
recombinant and endogenous proteins could be due to the
presence of six histidine residues and some extra amino
acid residues in recombinant PfSSB contributed by the
expression vector.
Comparison of the calculated molecular mass of mono-
meric form of recombinant PfSSB (25.2kDa) and en-
dogenous PfSSB (24.6kDa) with the estimated molecular
mass obtained from sucrose gradient experiments revealed
that both the recombinant PfSSB and endogenous PfSSB
would be in tetrameric form.
Further, DLS experiment was performed to evaluate
whether tetrameric form of PfSSB were present predom-
inantly in the solution. For this purpose, SSB protein from
gastric pathogen Helicobacter pylori was taken as positive
control. The molecular mass of HpSSB is  25kDa (close
to  His6-PfSSB,  25.2kDa) and it has been shown
recently that HpSSB exists as tetramer in solution (26).
DLS allows us to study the average particle size (hydro-
dynamic diameter) and its distribution in solution. The
average hydrodynamic diameter of Pf SSB was found to
be 152.1±2.65nm which is quite close to the hydro-
dynamic diameter 139.1±4.12nm of HpSSB
(Figure 2C). Thus, it can be inferred that majority of
PfSSB remains as tetramer as HpSSB in solution. These
results also reconﬁrm sucrose density gradient ultracentri-
fugation results.
Consistent with the tetrameric from of PfSSB as
obtained using various methods described earlier, we
performed the homology modelling of the protein using
EcSSB structure as template (29). Monomer model of
putative Oligo nucleotide Binding domain of PfSSB (80–
193 aa) is modelled using Modeller 9v7 software with the
Oligo nucleotide binding domain of EcSSB (ssDNA
bound subunit A1001–1112 of PDBID:1EYG) as a
template since it has signiﬁcant sequence homology
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Figure 2. Oligomeric properties of PfSSB. (A) Sucrose density gradient analysis of recombinant Pf SSB and endogenous Pf SSB. Recombinant PfSSB
was subjected to sucrose density gradient ultracentrifugation and different fractions were collected. Upper panel shows the coomassie stained
SDS–PAGE gel of recombinant protein of different fractions following sucrose density gradient. The lower panel shows the western blot analysis
of different fractions following sucrose density gradient ultracentrifugation of Plasmodium extract using anti-PfSSB antibodies. Arrowheads indicate
peak fractions of elution proﬁle of recombinant and endogenous PfSSB. Peak fractions of molecular mass markers following ultracentrifugation are
shown on the top. (B) The graph represents the standard curve of log of peak fraction number against log of molecular mass of known marker
proteins. (C) Dynamic light-scattering analysis of HpSSB and PfSSB. The right panel shows particle size distribution of HpSSB that indicates the
accumulation of a single species population of average hydrodynamic diameter of 139.1±4.125nm. The major population of Pf SSB is found to be
accumulated in the average hydrodynamic diameter of 152.133±2.65nm (left panel).
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superimposed using Dali pairwise structure alignment
program (http://ekhidna.biocenter.helsinki.ﬁ/dali/start)
onto individual monomer of tetramer (A–D subunits in
PDBID:1EYG) of EcSSB to generate the tetramer of
PfSSB with root mean square deviation (RMSD) of 1.8,
1.6, 2.0 and 1.8A ˚ , respectively. The model revealed three
conserved tryptophan residues (Trp-117, Trp-131 and
Trp-166) which are essential for ssDNA interaction. His
55 residue in EcSSB structure where it has been implicated
for oligomerization of SSB tetramer is also conserved in
PfSSB (His132) (29). The homology model of PfSSB
homotetrameric oligo binding domain is shown in
Figure 3 where different monomers (chains/subunits)
(A–D) are shown in different colours using Pymol
software. A homology model was also generated using
tetrameric form of PfSSB along with two stretches of
ssDNA (chains A and B) that shows the interaction
of ssDNA with the oligonucleotide binding domain of
PfSSB (Supplementary Figure S1B).
Complementation of E. coli ssb mutant cells with
wild-type and deletion mutant of PfSSB
In order to investigate whether PfSSB is a true homologue
of SSB in vivo, we performed genetic complementation
experiments using an E. coli ssb mutant strain with the
help of plasmid bumping experiment using EcSSB and
H. pylori SSB as positive control (26). The details of this
method are described in the ‘Materials and Methods’
section and the results are shown in Table 2. We found
that both EcSSB and HpSSB could complement this
mutant strain whereas PfSSB could not complement
under the same experimental conditions. Further, a
construct deleting the unique extreme C-terminal 28
residues present in PfSSB also cannot complement the
E. coli ssb mutant strain suggesting that PfSSB is inher-
ently different from EcSSB. It has been reported earlier
that the extreme 10 amino acid residues of EcSSB are es-
sential for its in vivo function (30). Poor homology at the
extreme C-terminal regions of these two proteins may con-
tribute to the inability of PfSSB to complement E. coli ssb
mutant strain.
In vitro and in vivo ssDNA binding activity of PfSSB
During DNA replication, recombination and repair, SSB
protein stabilizes the ssDNA intermediates. ssDNA
binding activity of puriﬁed recombinant PfSSB was moni-
tored using agarose gel mobility shift assay in the presence
of a mixture of M13 ssDNA and pUC18 dsDNA. The
results indicated that the mobility of single-stranded
M13 DNA was retarded signiﬁcantly with increasing
amount of PfSSB protein compared to pUC18 DNA
whose mobility did not change at all (Figure 4A).
Further, gel mobility shift assay was performed using
Chain A
Chain B Chain C
Chain D
Trp 167
Trp 131
Trp 117
His 132
Figure 3. Homology modelling of PfSSB. Pf SSB structure was modelled using the crystal structure of oligonucleotide binding domain of E. coli SSB
as template. The positions of the conserved amino acid residues (Trp-117, Trp-131, Trp-167 and His-132) are shown in the ﬁgure. Four monomers of
SSB that form the tetramer are shown in different colours (chains A–D). The model also shows two ssDNA molecules (A and B) interacting with the
tetramer model.
Table 2. Complementation experiments results
Test ssb Total no
of patches
Amp
R Amp
R+Tc
R Percentage of
plasmid bumping
efﬁciency (%)
pTRC+Ecossb(+ve) 40 40 4 90
pTRC( ve) 40 40 38 5
pTRC+Hpssb 40 40 6 85
pTRC+Pfssbwt 40 40 37 7.5
pTRC+PfssbC28 40 40 38 5
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Figure 4. In vitro and in vivo DNA binding property of Pf SSB. (A) PfSSB binds speciﬁcally to ssDNA. Different amount of Pf SSB was incubated
with the mixture of M13 mp18 ssDNA and pUC18 dsDNA followed by separation of the protein-DNA complex by agarose gel electrophoresis.
ssDNA was progressively retarded (asterisk) with increasing concentration of PfSSB whereas mobility of dsDNA was not affected.
(B) Electrophoretic mobility shift assay using short radiolablled single-stranded oligonucleotide probe with increasing amount of Pf SSB. The
arrowhead indicates the protein bound DNA. (C) Gel retardation analysis of single stranded DNA binding activity from P. falciparum cell
extract. Labelled ssDNA probe was incubated with P. falciparum cell extract in the absence or presence of anti-PfSSB or anti-PCNA antibodies
or pre-immune sera against SSB followed by PAGE analysis of the protein–DNA complexes (shown by arrowhead). Supershift of the DNA–protein
complex was observed only in the presence of immune sera against PfSSB (lane 4) but not in the presence of pre-immune sera (lane 3) or
non-immune sera (anti-PCNA) (lane 5). (D) Single-stranded DNA binding activity of cytoplasmic or nuclear extract or immunodepleted samples
from each fraction in the presence of preimmune and immune sera against PfSSB. A single shifted band of labelled probe was observed in
cytoplasmic fraction (lane 2) whereas two such bands were observed in nuclear extract treated samples (lane 3). No band was observed in the
presence of immunodepleted cytoplasmic extract (lane 5) whereas the bottom band was not visible in the presence of immunodepleted nuclear extract
treated sample (lane 7). Pre-immune depleted samples did not affect the pattern of bands (lanes 4 and 6) found in extract only lanes (lanes 2 and 3).
(E) The upper part of the left panel shows the western blot analysis of immune and pre-immune depleted Plasmodium cytoplasmic extract whereas
the lower part represents the coomassie stained gel as loading control following transfer of the proteins on the membrane. Similarly, the upper part
of the right panel shows the western blot analysis of the immunodepleted nuclear extract (immune and pre-immune treated) and the lower part of the
same panel represents the coomassie stained gel as loading control. The arrowhead indicates the position of the PfSSB protein. (F) Speciﬁc binding of
PfSSB to apicoplast DNA in ChIP assay. PCR ampliﬁcation of ori region of apicoplast (api.) DNA was found only in the immunoprecipitated
samples using immune sera (I) against PfSSB but not with the pre-immune (PI) sera whereas nuclear (nuc.) ssb gene could not be ampliﬁed using ssb
gene speciﬁc primers (set 1). Further, PCR ampliﬁcation of immunoprecipitated DNA along with input (inp.) genomic DNA were performed using
speciﬁc primer sets from nuclear orc5, apicoplast ori and IRA region (set 2) or nuclear sir2 and apicoplast tufA regions (set 3). Speciﬁc products were
found only in the immunoprecipitated samples using immune sera and primer sets from apicoplast DNA. No signiﬁcant ampliﬁcation was found
using primer sets from nuclear DNA. PCR products were obtained in all the control input lanes.
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similar results as above where increasing amount of
PfSSB results major shift of the ssDNA probe
(Figure 4B). We also investigated whether P. falciparum
extract would contain ssDNA binding activity contributed
by PfSSB. For this purpose, radiolabelled ssDNA probe
(70 mer) was incubated with P. falciparum parasite extract
followed by PAGE analysis of the reaction mixture. We
ﬁnd that P. falciparum extract cause a considerable shift of
the ssDNA probe (lane 2, Figure 4C). To identify whether
this binding is speciﬁc for PfSSB, the reaction mixture was
incubated further in the presence of undiluted anti-PfSSB
or pre-immune sera as described in the ‘Materials and
Methods’ section. We ﬁnd, while pre-immune sera do
not affect the ssDNA binding activity, immune sera
causes a supershift suggesting that the binding is speciﬁc
for PfSSB (lanes 3 and 4, Figure 4C). Non-immune
PfPCNA antibodies also do not affect the ssDNA
binding activity further conﬁrming the presence of
speciﬁc PfSSB like ssDNA binding activity in the P. fal-
ciparum extract.
Speciﬁc interaction of the high molecular mass contain-
ing tetrameric form of PfSSB with high titer antibodies
against PfSSB may form huge complex causing supershift
of the DNA–protein complex that may not enter the poly-
acrylamide gel properly as shown above. The supershift
experiments were repeated with some modiﬁcations like
using different concentrations of diluted PfSSB antibodies
(1–5ml of 1:1000 diluted anti-PfSSB sera in 1  PBS) and
resolving the DNA–protein complex for a longer time
during PAGE analysis. We ﬁnd that pre-immune sera
against PfSSB do not show any supershifted band even
at the highest concentration whereas immune sera show
speciﬁc supershifted bands at all concentrations. However,
with increasing concentration of immune sera, the inten-
sity of the original DNA–protein complex is reduced sig-
niﬁcantly with the appearance of a higher molecular mass
containing population that does not enter the gel properly
apart from the supershifted band that entered the gel
(Supplementary Figure S2). The complex that does not
enter the gel may be the result of the accumulation of
huge complex containing ssDNA–Protein-Ab at the
higher concentration of antibodies.
To conﬁrm whether the ssDNA binding activity present
in P. falciparum parasite extract is due to the presence of
PfSSB, sub-cellular fractionation of the parasite extract
was performed to obtain cytoplasmic extract and nuclear
extract as described earlier (31). Each fraction was
immunodepleted using immune and pre-immune sera
against PfSSB. Immunodepleted cytoplasmic and nuclear
extract were used for gel retardation assay using labelled
ssDNA probe. We ﬁnd that cytoplasmic extract yields one
shifted band whereas nuclear extract results in two shifted
bands. An extra band was obtained on top of the band
corresponding to the band obtained from the cytoplasmic
extract (lanes 2 and 3, Figure 4D). Immunodepleted cyto-
plasmic extract using PfSSB immune sera resulted in
complete loss of DNA binding activity (lane 5).
Interestingly, immunodepleted nuclear extract resulted in
the loss of band corresponding to the band obtained in
cytoplasmic extract. However, the upper band obtained
in nuclear extract was not affected following
immunodepletion suggesting the shift represented by
upper band would not be due to the presence of PfSSB
(lanes 6 and 7, Figure 4D). This ssDNA binding activity
could be due to the presence of speciﬁc nuclear protein
present in the nuclear extract. This could be due to the
presence of RPA in the nuclear fraction as it has been
reported earlier (20). Immunodepletion of cytoplasmic
extract was further conﬁrmed by western blot analysis of
pre-immune and immune sera depleted cytoplasmic
extract using anti-PfSSB antibodies (Figure 4E, left
panel). The results indicate the presence of a strong
band corresponding to PfSSB in the pre-immune sera
depleted sample compared to the very weak band
present in the immune-sera depleted sample. The similar
loading in both the lanes is indicated by the coomassie
stained gel following transfer of the proteins onto the
membrane. Immunodepletion of nuclear extract using
pre-immune sera and PfSSB antibodies followed by
western blot analysis indicate the presence of PfSSB in
the nuclear extract possibly as a contamination of
nuclear fraction with cytoplasmic proteins (Figure 4E,
right panel) that may have resulted the appearance of
the lower band in the gel shift assay using nuclear
fraction as shown earlier. These results indicate that the
speciﬁc immunodepletion of PfSSB from the cytoplasmic
extract may have caused the inability of the
immunodepleted extract to bind to ssDNA.
We further investigated whether PfSSB binds speciﬁcal-
ly to apicoplast DNA in vivo. For this purpose, ChIP ex-
periments were performed using pre-immune or immune
sera against PfSSB. Recently a similar approach has
worked nicely to show that PfGyrB binds speciﬁcally to
its target apicoplast DNA with no afﬁnity towards nuclear
DNA (22). ChIP results indicate that PfSSB binds
strongly to the apicoplast ori region compared to the
nuclear ssb gene as control (Figure 4F, set 1). ChIP ex-
periments were repeated several times followed by PCR
using primer sets from different nuclear loci and
apicoplast loci. We ﬁnd that the intensity of the PCR
product using primer set from apicoplast DNA is always
higher many fold than that obtained from nuclear DNA in
different sets of experiments (Figure 4F, sets 2 and 3).
These results indeed suggest that PfSSB binds speciﬁcally
to apicoplast DNA as compared to nuclear DNA.
Modulation of PfSSB expression and activity in the
presence of inhibitors against apicoplast machinery
Plasmodium contains both the subunits of prokaryote type
gyrase (a and b) that are nuclear encoded but targeted to
the apicoplast (11). Gyrase is required for the maintenance
of the apicoplast DNA as positive supercoils are generated
ahead of the replication fork that should be relieved inter-
mittently for the faithful replication of apicoplast DNA. It
has been shown earlier that ciproﬂoxacin, a gyrase A
speciﬁc inhibitor affects the apicoplast DNA replication
speciﬁcally without affecting nuclear DNA replication
(32). Interestingly, ciproﬂoxacin shows typical delayed
death phenotype of the parasites where parsitemia drops
signiﬁcantly during the second life cycle of the parasites
7046 Nucleic Acids Research, 2010,Vol.38, No. 20following the addition of the drug without affecting the
parasites during the ﬁrst life cycle (13). We were interested
to study whether ciproﬂoxacin would modulate PfSSB
function since it is also a key molecule for apicoplast
DNA replication.
We ﬁrst investigated the effect of ciproﬂoxacin on
parasite growth during ﬁrst and second life cycle of
parasite development. Although ciproﬂoxacin caused
 40% decline in parasitemia at 15mM concentration, it
did not cause any signiﬁcant effect at lower drug concen-
tration (5/10mM) at the end of the ﬁrst life cycle ( 48h).
However, at the end of the second life cycle ( 92h), there
was a dramatic drop in parasitemia at 5/10mM drug con-
centration that resembled the delayed death effect of
ciproﬂoxacin as described earlier (Figure 5A) (13).
It has been reported earlier that drugs that affect
apicoplast housekeeping functions (e.g. tetracycline),
inhibit the translocation of the proteins to the apicoplast
(during second life cycle) using signal sequence of ACP
fused to GFP as marker (14,15). No endogenous
apicoplast targeted protein has been tracked in the
above studies. We were interested to investigate whether
treatment of the parasites with ciproﬂoxacin would
modulate PfSSB translocation and function.
Subsequently, we performed western blot analysis using
ciproﬂoxacin (10mM) treated parasite lysate obtained
from ﬁrst life cycle ( 34h post-drug treatment) and
second life cycle ( 82h post-drug treatment) by using
antibodies raised against PfSSB. Antibodies against
PfActin and PfPCNA were used as control for western
blot experiments. We ﬁnd that during the ﬁrst life cycle,
addition of ciproﬂoxacin does not change the expression
of PfSSB protein compared to the untreated parasites
(Figure 5B). However, during second life cycle, the expres-
sion of PfSSB is found to be reduced in ciproﬂoxacin
treated parasites compared to the untreated parasites.
In contrary, the expression level of control protein
PfActin and nuclear replication protein PfPCNA did not
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Figure 5. Modulation of PfSSB expression and activity in the presence of apicoplast inhibitors. (A) The graph shows the parasitemia (%) at different
time points in the absence and presence of different concentration of gyrase inhibitor ciproﬂoxacin. (B) Western blot analysis using anti-PfSSB
antibodies to show the effect of ciproﬂoxacin on the expression of PfSSB at protein level during ﬁrst life cycle (34h) and second life cycle (82h).
There was overall decrease in PfSSB protein level as well as appearance of an extra band (asterisk) during second life cycle in ciproﬂoxacin treated
samples. The expression proﬁle of PfActin and nuclear PfPCNA are also shown as controls. (C) The left panel shows the expression proﬁle PfSSB at
different time points along with control PfActin in the absence and presence of ciproﬂoxacin. ‘Asterisk’ indicates the unprocessed form of SSB. The
right panel shows the effect of artimisinin at different concentration on PfSSB and PfActin expression. Artimisinin does not seem to have any effect
on PfSSB expression. (D) Western blot analysis using parasite lysate obtained from ciproﬂoxacin (cip) or tetracycline (tet) treated or untreated
samples in the presence of anti-PfSSB or anti-PfHU (histone like protein) or PfActin antibodies. ‘Asterisk’ indicates the unprocessed form of HU and
PfSSB. (E) Effect of ciproﬂoxacin on ssDNA binding activity from Plasmodium extract. The left panel shows the western blot analysis using
anti-PfSSB antibodies with or without drug treatment along with actin as control. The right panel shows the gel retardation assay using parasite
lysate from cip. treated and untreated samples.
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band is observed in drug treated samples that is absent in
the untreated samples (Figure 5B). This may be the un-
processed form of PfSSB before the cleavage of signal
peptide and transit peptide required for the faithful trans-
location of apicoplast proteins. Apicoplast speciﬁc drugs
often result in accumulation of the immature form of the
apicoplast targeted proteins during second life cycle (15).
However, the decrease in overall PfSSB protein level
during second life cycle following ciproﬂoxacin treatment
is very striking.
The previous experiment did not allow us to investigate
the timing of the effect of ciproﬂoxacin on PfSSB protein
level during second life cycle. For this purpose,
ciproﬂoxacin treated or untreated parasite pellets were
obtained from the trophozoite ( 68h post-drug treat-
ment) and schizont stages ( 82h post-drug treatment)
during the second life cycle followed by analysis of the
PfSSB protein level by western blot analysis using
anti-PfSSB antibodies (Figure 5C, left panel). Parasite
lysate from the ﬁrst life cycle was also taken as control.
We ﬁnd that the expression level of PfSSB protein is
reduced even at the trophozoite stage that continues
until schizont stage during second life cycle whereas the
PfActin level does not change at all. A faint band corres-
ponding to unprocessed form of PfSSB was also visible at
the latter stage.
We further show that the decrease in overall PfSSB
protein level and the appearance of the mature form of
PfSSB following ciproﬂoxacin treatment is speciﬁc for
apicoplast targeted drugs. Use of increasing amount of
artemisinin that cause considerable parasitic death result-
ing in huge decrease in parasitemia does not affect the
level of PfSSB at all. Neither the mature form of PfSSB
could be detected even at the highest concentration of
artimisinin used (30nM) (Figure 5C, right panel).
We are interested to ﬁnd out whether modulation of
PfSSB expression and maturation is ciproﬂoxacin-speciﬁc
or it is a manifestation of apicoplast targeted drugs to
modulate apicoplast targeted proteins in general. For
this purpose, we performed western blot analysis using
ciproﬂoxacin and tetracycline (protein translation inhibi-
tor that also affects apicoplast) treated parasite extract in
the presence of PfSSB and PfHU (histone like protein)
antibodies. Western blot analysis indicates that the treat-
ment of ciproﬂoxacin and tetracycline affects the expres-
sion and maturation of both PfSSB and PfHU protein to
the similar extent (Figure 5D). However, these drugs did
not have any effect on control protein PfActin.
Further, to investigate whether ciproﬂoxacin truly
affects the translocation of apicoplast targeted proteins
like PfSSB during second life cycle, we have performed
immunoﬂuorescence assay using untreated and drug
treated parasites in the presence of PfSSB antibodies.
We ﬁnd speciﬁc apicoplast localized PfSSB signal in the
untreated parasites whereas the apicoplast localization of
PfSSB is severely affected in the drug-treated parasites
under the same experimental conditions (Supplementary
Figure S3). These results strongly suggest that
cirpoﬂoxacin inhibits the translocation of SSB during
second life cycle.
The above results prompted us to investigate whether
parasite extract obtained from ciproﬂoxacin treated para-
sites would yield ssDNA binding activity. This would also
help us to conﬁrm whether the ssDNA binding activity
from the parasite extract is truly dependent on PfSSB.
Gel retardation assay was performed using parasite
extract obtained from ciproﬂoxacin treated and untreated
control parasites. We ﬁnd a strong shift of the
radiolabelled probe in the presence of untreated parasite
extract compared to the free probe. Interestingly,
ciproﬂoxacin treated parasite extract fails to show any
prominent shifted band suggesting that the inability of
ssDNA binding may be attributed to the poor presence
of the mature form of PfSSB in ciproﬂoxacin treated
samples (Figure 5E, right panel). Western blot analysis
using extract obtained from ciproﬂoxacin treated and un-
treated parasites in the presence of PfSSB antibodies
further conﬁrm the above results (Figure 5E, left panel).
Synthesis of SSB protein is affected during second life
cycle following ciproﬂoxacin treatment
We ﬁnd that apicoplast targeted drug, ciproﬂoxacin
affects the translocation of the proteins to the apicoplast
as evidenced by the accumulation of the unprocessed form
of the protein in the presence of the drug. It is also inter-
esting that there is an overall decrease ( 4-fold) in PfSSB
protein level compared to control protein PfActin follow-
ing drug treatment (Figure 6A). Transcription of ssb is
up-regulated in E. coli cells in the presence of ciproﬂoxacin
(33). It is possible that the decrease in SSB protein level
following ciproﬂoxacin treatment during second life cycle
is caused by the reduced transcription of Pfssb in the
nucleus. To address this issue, we performed semi-
quantitative RT-PCR analysis using cDNA prepared
from ciproﬂoxacin treated and untreated samples. We
ﬁnd that there is no signiﬁcant difference in the transcript
level of ssb in the presence or absence of ciproﬂoxacin
(Figure 6B). PfGAPDH was used as control that also
did not change its expression as ssb. These results
indicate that down-regulation of SSB protein in the
ciproﬂoxacin treated parasites may not be due to the tran-
scriptional defect. This is consistent with the earlier pub-
lished results where the microarray analysis of tetracyclin
treated parasites do not show change in transcription level
of nuclear genes (including genes required for nuclear
encoded apicoplast-targeted proteins) compared to the un-
treated parasites (14). The other possibility is that SSB
protein was degraded with time leading to the decrease
in protein level. We used MG132, a proteosomal degrad-
ation pathway inhibitor during the second life cycle fol-
lowing ciproﬂoxacin treatment. Recently, we have shown
that MG132 can stabilize PfORC1 by inhibiting degrad-
ation of PfORC1 at the late schizont stage (34). Western
blot analysis using parasite lysate obtained from 100nM
MG132 treated and untreated samples (during second
cycle following ciproﬂoxacin treatment) reveals that
MG132 does not change the SSB protein level (Figure
6C) suggesting that the decrease in SSB protein level
would not be due to the degradation of the protein.
MG132 was active in the parasites as addition of similar
7048 Nucleic Acids Research, 2010,Vol.38, No. 20concentration of drug could stabilize PfORC1 from deg-
radation at the late schizont stage as shown by immuno-
ﬂuorescence and western blot analysis (Supplementary
Figure S4A and B).
These results suggest that the decrease in the SSB
protein level during the second life cycle following
ciproﬂoxacin treatment might be attributed to the
translational defect. To address this issue further,
ciproﬂoxacin-treated or untreated parasites were
incubated in the presence of
35S-methionine during
second life cycle (trophozoite stage,  68h post-drug treat-
ment) for 3h. The parasite lysate were obtained from both
control and drug-treated parasites followed by SDS–
PAGE analysis and autoradiography to visualize the
labelled proteins. The results indicate that there is no
gross change in the metabolic labelling of the proteins
during second life cycle in the presence or absence of the
drug (Figure 6D, left panel). The above lysate were used to
immunoprecipitate newly synthesized SSB protein during
second life cycle using pre-immune and immune sera
against SSB. We ﬁnd that SSB can be immunoprecipitated
speciﬁcally using immune sera but not pre-immune sera
during second life cycle from the untreated sample only
(Figure 6D, right panel). Interestingly, PfActin can be
immunoprecipitated from both the untreated and
drug-treated sample to the similar extent using speciﬁc
antibodies against PfActin under the similar experimental
conditions (Figure 6D, middle panel). We also performed
immunoprecipitation experiments using pre-immune and
immune sera against PfHU under the same experimental
conditions. We ﬁnd that the translation of newly
synthesized PfHU protein during second life cycle
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Figure 6. (A) Comparison of expression level of PfSSB and PfActin in the absence and presence of ciproﬂoxacin for three different set of experi-
ments. Western blot experiments were performed using parasite lysate obtained from ciproﬂoxacin (10mM) treated or untreated parasites in the
presence of antibodies against PfSSB and PfActin. The relative intensity of the bands was measured using densitometry scanning followed by
graphical representation of them to show the fold change in the expression level. (B) RT-PCR analysis of PfSSB and PfGAPDH transcript level from
the parasites treated with cip. or untreated parasites. RT ( ) indicates the cDNA prepared from total RNA samples treated without reverse
transcriptase. (C) Western blot analysis to evaluate the effect of proteosome inhibitor MG132 on PfSSB expression. Parasites treated with
ciproﬂoxacin were further treated with MG132 during second life cycle before harvesting for western blot analysis. The results indicate that treatment
with MG132 does not change the PfSSB protein level. The same blot was reprobed with anti-PfActin antibodies as control. (D) Status of newly
synthesized PfSSB during second life cycle following ciproﬂoxacin treatment. Ciproﬂoxacin treated or control parasites were incubated in the
presence of
35S-methionine for 3h during the trophozoite stage of the second life cycle ( 68h post-drug treatment) followed by immunoprecipitation
analysis of PfSSB or PfActin or PfHU proteins using respective pre-immune (PI) or immune (I) sera from control or drug treated parasite lysate. The
total parasite lysate obtained from untreated and drug treated
35S-methionine labelled parasites were loaded as input (inp.). The results indicate that
the expression of newly synthesized PfSSB and PfHU is affected signiﬁcantly without affecting the expression of PfActin under the same experimental
conditions.
Nucleic Acids Research, 2010,Vol.38, No. 20 7049following drug treatment is also signiﬁcantly reduced
compared to the untreated samples (Figure 6D, bottom
panel). These results suggest although there is no signiﬁ-
cant change in protein expression proﬁle during tropho-
zoite stage of the second life cycle between drug-treated
and untreated samples, there is a speciﬁc down-regulation
of translation of nuclear encoded apicoplst targeted
proteins like SSB and HU during second life cycle follow-
ing ciproﬂoxacin treatment. It is important to note that all
apicoplast targeted proteins may not be affected to the
similar extent at a particular time since there may be add-
itional mechanisms to control their expression proﬁle that
need to be explored further.
DISCUSSION
The replication of apicoplast DNA circle begins in tropho-
zoite stage and continues into schizogony (5). Very little is
known about the process and enzymology involved in the
replication of apicoplast genome. So far, few enzymes
including gyrase and PfPRex have been reported that
could be the members of active replication/recombination
machinery within the apicoplast. This study is an attempt
to identify and functionally characterize another key
DNA replication protein, the ssDNA binding protein in
P. falciparum. To our knowledge, the identiﬁcation of SSB
in P. falciparum is the ﬁrst report of the presence of bac-
terial type SSB in any eukaryotic parasite. In E. coli and
other prokaryotes, in addition to DNA replication the role
of SSB has been extended to DNA recombination and
repair events. PfSSB may be involved in these processes
to maintain the apicoplast genome.
It is known that SSB protein binds to circular super-
coiled DNA containing ssDNA stretches that have been
induced by topological stress generated by different
cellular processes like DNA replication, transcription
and recombination (35). Our data suggest that PfSSB is
exclusively targeted to the apicoplast and it binds to the
apicoplast DNA and not to the nuclear DNA. Together,
these data conﬁrm apicoplast speciﬁc role of PfSSB. The
apicoplast DNA replication occurs in the late
trophozoite-early schizont stages. However, PfSSB is con-
stitutively expressed and localized into the apicoplast
during all the three stages of intraerythrocytic develop-
mental cycle of P. falciparum. This may explain the
possible involvement of PfSSB in different DNA transac-
tions other than DNA replication during the
non-replicative phases of intra-erythrocytic parasitic life
cycle (ring, early trophozoite).
Earlier, ssDNA binding activity from P. falciparum had
been assigned to large subunit of RPA. The ssDNA
binding activity exhibited by RPA has been shown to be
present in both nuclear and cytoplasmic fractions.
However, speciﬁcity of the ssDNA binding activity could
not be tested due to the non-availability of speciﬁc
antibodies against RPA. In contrast, we show that the
ssDNA binding activity from cytoplasmic fraction is
largely contributed by PfSSB. The loss of ssDNA
binding activity in immunodepleted cytosolic fraction
using speciﬁc anti-PfSSB antibodies strongly substantiates
our claim.
There are two ssDNA binding activities in nuclear
fraction and only one of them is contributed by PfSSB.
We show that upon immunodepletion of PfSSB from the
nuclear extract, the ssDNA binding activity contributed
by PfSSB is completely lost whereas the other activity
remains unaffected. The unaffected ssDNA activity in
the nuclear extract may probably be due to RPA as
reported earlier (20). However, we cannot rule out the
ssDNA binding activity by PfSSB in the nuclear extract
by cross-contamination of cytoplasmic PfSSB during the
cell fractionation because our ChIP experiment using
speciﬁc anti-PfSSB antibodies yield robust ampliﬁcation
of apicoplast DNA only and no signiﬁcant ampliﬁcation
of nuclear DNA.
Generally, SSB modulates the functions of other repli-
cation/recombination/repair proteins by interacting with
them via acidic C-terminus region. It has been reported
that the last 10 amino acid residues of SSB are highly
conserved among different bacteria and they are essential
for in vivo protein–protein interaction (30). The
C-terminus of PfSSB shows little sequence conservation
and there is an extension of 28 amino acid residues.
Poor sequence conservation at the C-terminus of PfSSB
may explain its failure to complement E. coli ssb function
in vivo. The identiﬁcation of the proteins interacting with
PfSSB C-terminus would be an essential step towards
understanding the role of PfSSB during different develop-
mental stages of the parasite erythrocytic life cycle, par-
ticularly during the ring stage where DNA replication
does not take place.
PfSSB forms tetramer in solution similar to EcSSB.
His-55 and the region between amino acid residues
89–105 have been suggested to have a role in
tetramerization of EcSSB. In PfSSB, His-132 is equivalent
to His-55 of EcSSB and the region between 165 and
194 shows a signiﬁcant homology with the region
89–105 of EcSSB. These similarities may explain the tetra-
meric nature of the protein both in vitro and in vivo as
shown here. Our ongoing crystallization studies of
PfSSB may provide a clear insight into oligomerization
interfaces of the protein.
Ciproﬂoxacin is a quinolone antibiotic that principally
targets DNA gyrase and results in the breakage of the
P. falciparum apicoplast DNA without affecting the
nuclear DNA during second life cycle at an IC50 of
 7mM. Surprisingly, our results indicate that blocking
apicoplast replication with ciproﬂoxacin results in the
drastic reduction in the levels of PfSSB and its transloca-
tion to the apicoplast as evidenced by the accumulation of
PfSSB with the signal peptide sequence. However,
ciproﬂoxacin treatment does not change the levels of cyto-
plasmic actin and nuclear replication protein PCNA1. The
level of PfSSB is not affected when the parasites are
treated with commonly used non-apicoplast targeted
anti-malarial drug artemisinin, suggesting that the drug
stress does not lead to the decrease in PfSSB levels.
However, treatment of the parasites with tetracycline
that affects apicoplast translation also modulates PfSSB
expression and maturation like ciproﬂoxacin suggesting
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fere with the translocation of the proteins to the apicoplast
and the protein level. The similar fate of HU, another
protein targeted to the apicoplast, following ciproﬂoxacin
and tetracyclin treatment further conﬁrms the generalized
mechanism of apicoplast targeted drugs. Simultaneous
treatment of parasites with ciproﬂoxacin and proteosome
blocker MG132 clearly indicates that protein is not
degraded in the presence of ciproﬂoxacin during the
second cycle. Moreover, the inhibition of apicoplast
DNA replication does not affect the level of the ssb tran-
scripts produced in the nucleus housing ssb gene on ChrV
as shown by the semi-quantitative RT-PCR analysis.
Incubation of the parasites with
35S-methionine to track
the newly synthesized proteins during second life cycle
suggests that translation of SSB and HU transcripts are
speciﬁcally affected during second life cycle following drug
treatment although both untreated and drug-treated para-
sites show comparable protein expression proﬁle and there
is no change in expression level of control PfActin protein.
Like PfSSB, the expression level of newly synthesized
PfHU protein during the second life cycle following drug
treatment was severely affected. It seems that apicoplast
targeted drug ciproﬂoxacin may selectively inhibit the
translation of apicoplast targeted proteins during second
life cycle without affecting the translation of other
proteins. It remains to be seen further, how this differen-
tial regulation of translation is maintained in the parasites.
This work shed some light to understand the mechanism
behind the delayed death phenomena showed by some
drugs like ciproﬂoxacin and tetracycline that affect
apicoplast function. The parasites undergo normal
division and segregation of organelles during the ﬁrst life
cycle. However, severe defects in apicoplast growth,
morphology and cytokinesis take place in the second life
cycle. Consistent with the above results, we ﬁnd that the
translocation of apicoplast targeted proteins like SSB is
not affected during the ﬁrst life cycle. It is possible that the
accumulation of the drugs in the four membrane bound
apicoplast is a slow process and the parasites can bypass
the ﬁrst life cycle since the drug may be limiting and it may
not reach the critical concentration that may affect the
apicoplast function immediately. There is also a constant
translocation of fresh proteins from the cytoplasm to the
apicoplast during this stage. However, during the second
life cycle, the parasites may acquire the critical concentra-
tion of the drugs that may affect the apicoplast function,
growth and morphology, which in turn affect the protein
translocation in the apicoplast, leading to the accumula-
tion of the unprocessed form of the proteins in the cyto-
plasm. This, in turn may be sensed by the cytoplasmic
translational machinery involved in synthesis of apicoplast
targeted proteins, to selectively reduce their synthesis.
Latter, the complete inhibition of apicoplast function
and growth may affect overall growth of the parasite
leading to the parasitic death since apicoplast is the indis-
pensable organelle of the parasite involved in various im-
portant pathways like fatty acid synthesis and heam
biosynthesis. Therefore, dual mechanism consisting of
translocation and translation defect of apicoplast
targeted proteins during second life cycle may contribute
to the delayed death phenomena shown by some
apicoplast targeted drugs like ciproﬂoxacin and tetracyclin
(Figure 7). Although ciproﬂoxacin is a speciﬁc inhibitor of
gyrase, it remains to be seen further whether ciproﬂoxacin
has a direct effect on the translational machinery during
second life cycle following drug treatment.
To understand the fundamental process of apicoplast
DNA replication completely, it is essential to identify all
the key enzymes and study their role for the replication of
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Figure 7. Model showing the effect of ciproﬂoxacin on parasites. In the absence of apicoplast targeted drug like ciproﬂoxacin, nuclear encoded
apicoplast targeted (NEAT) genes are transcribed in the nucleus (N) and transported into the cytoplasm (C) where they are translated as unprocessed
protein that are translocated to the apicoplast (A) and gets processed. During second life cycle following drug treatment, the apicoplast achieve
critical concentration of the drug that affects apicoplast function and morphology that inhibits translocation of NEAT proteins into the apicoplast
which in turn may down-regulate the translation of these proteins. Therefore, a dual mechanism of inhibition of translocation of NEAT proteins and
modulation of translation level of these proteins may contribute to the delayed death effect exerted by such drugs like ciproﬂoxacin. The solid and
broken circles in apicoplast indicate the apicoplast genome in the absence and presence of drug.
Nucleic Acids Research, 2010,Vol.38, No. 20 705135kb DNA circle. Our results provide conclusive evidence
that apicoplast imports a bacterial homologue of nuclear
encoded ssDNA binding protein that could be required in
ssDNA intermediate stabilization during the process of
DNA replication. The apicoplast localized PfSSB can be
used as a tool to identify other components of the repli-
cation machinery as its homologue in bacteria has been
shown to interact and modulate the activities of different
members of replication proteins during the fork
progression.
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